Cas:81352-25-2 (2R,3R,4S,5R)-2-(6-aminopurin-9-yl)-5-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]oxolane-3,4-diol manufacturer & supplier

Chemical Name:(2R,3R,4S,5R)-2-(6-aminopurin-9-yl)-5-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]oxolane-3,4-diol

CAS.NO:81352-25-2

Synonyms:5′-O-dimethoxytrityladenosine;5′-O-(p,p’-dimethoxytrityl)adenosine;Adenosine,5′-O-[bis(4-methoxyphenyl)phenylmethyl];5′-O-DMT-adenosine;5′-O-(4,4′-dimethoxytrityl)-adenosine;5′-O-[Bis(4-methoxyphenyl)phenylmethyl]-adenosine

Molecular Formula:C₃₁H₃₁N₅O₆

Molecular Weight:569.60800

HS Code:2934999090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:147.00000

Exact Mass:569.22700

LogP:3.63480

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 5′-O-dimethoxytrityladenosine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,5′-O-[Bis(4-methoxyphenyl)phenylmethyl]-adenosine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,5′-O-DMT-adenosine Use and application,5′-O-(p,p’-dimethoxytrityl)adenosine technical grade,usp/ep/jp grade.

Related News: As proof-of-principle for the unique advantages arising from selecting a single engineered iPSC clone for the production of CAR T-cell therapy, the scientists assessed 747 clones after engineering a pool of cells using CRISPR. It was found that only about 2% of clones met the Company��s standards for overall quality including containing both bi-allelic disruption of the TCR, proper insertion of the CAR into the TRAC locus without random transgene integrations, and no evidence of off-target genomic modifications or translocations. (2R,3R,4S,5R)-2-(6-aminopurin-9-yl)-5-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]oxolane-3,4-diol manufacturer As a result, the Company��s platform is uniquely capable of overcoming numerous limitations associated with the production of cell therapies using patient- or donor-sourced cells, which is logistically complex and expensive and is subject to batch-to-batch and cell-to-cell variability that can affect clinical safety and efficacy. (2R,3R,4S,5R)-2-(6-aminopurin-9-yl)-5-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]oxolane-3,4-diol supplier While they are early data, “it’s also very reassuring that those patients who have progressed can be rather easily reinduced into remission,” Tendler said. J&J and AbbVie are now taking the same approach for the GLOW study, he added. (2R,3R,4S,5R)-2-(6-aminopurin-9-yl)-5-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]oxolane-3,4-diol vendor As proof-of-principle for the unique advantages arising from selecting a single engineered iPSC clone for the production of CAR T-cell therapy, the scientists assessed 747 clones after engineering a pool of cells using CRISPR. It was found that only about 2% of clones met the Company��s standards for overall quality including containing both bi-allelic disruption of the TCR, proper insertion of the CAR into the TRAC locus without random transgene integrations, and no evidence of off-target genomic modifications or translocations. (2R,3R,4S,5R)-2-(6-aminopurin-9-yl)-5-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]oxolane-3,4-diol factory The glucagon-only configuration may be helpful in rare conditions that often lead to chronic, low blood-sugar conditions, such as congenital hyperinsulinism (CHI).